Bemlih et al. found that avasimibe targets ACAT1 to inhibit tumor cell growth and induce apoptosis in glioblastoma 283, as well as depleting CEs in prostate cancer and impairing the Wnt/β-catenin pathway, which inhibits metastasis 284. The gene discussed is ACAT1; the disease is neoplasm.